|
Chỉ định và Liều dùng
Intravenous
Advanced ovarian carcinoma, Small cell lung cancer Adult: Previously untreated patients: 400 mg/m2 as single short term IV infusion over 15-60 min. Therapy should not be repeated until 4 wk after the previous course and/or until the neutrophil count is at least 2,000 cells/mm3 and the platelet count is at least 100,000 cells/mm3. Patients previously treated w/ myelosuppresive therapy or patients w/ poor performance status: Reduce initial dosage by 20-25% (300-320 mg/m2).
|
||||||
|
Suy thận
|
||||||
|
Tương kỵ
Carboplatin reacts w/ Al causing loss of potency and forming a precipitate, do not use needles, syringes, catheters, IV admin sets containing Al parts. Incompatible w/ amphotericin B cholesteryl sulfate complex.
|
||||||
|
Chống chỉ định
Hypersensitivity to carboplatin or other platinum-containing compd (e.g. cisplatin). Patient w/ severe bone marrow depression or significant bleeding; bleeding tumours. Concomitant use w/ yellow fever vaccine.
|
||||||
|
Thận trọng
Renal impairment. Pregnancy and lactation.
|
||||||
|
Tác dụng không mong muốn
Bone marrow suppression (thrombocytopenia, neutropenia, leucopenia), anaemia; nausea, vomiting, abdominal pain, diarrhoea, constipation, mucous membrane disorder; decreased CrCl, blood Na, K, Ca, and Mg; increased blood urea, blood alkaline phosphatase, aspartate aminotransferase, abnormal LFTs; infections, resp disorder, interstitial lung disease, haemorrhage, ototoxicity; alopecia, skin disorder, musculoskeletal disorder, asthenia, urogenital disorder; peripheral neuropathies, paraesthesia, decreased osteotendinous reflexes, visual disturbances (including vision loss), sensory disturbances, dysgeusia.
Potentially Fatal: Anaphylactic-type reactions (e.g. facial oedema, dyspnoea, tachycardia, low BP, urticaria, anaphylactic shock, bronchospasm), CV events including cardiac failure, embolism and cerebrovascular accident. |
||||||
|
IV/Parenteral: D
|
||||||
|
Thông tin tư vấn bệnh nhân
This drug may cause nausea, vomiting, vision abnormalities and ototoxicity, if affected, do not drive or operate machinery.
|
||||||
|
Chỉ số theo dõi
Determine haematologic nadir by wkly blood counts during initial courses. Closely monitor hepatic and renal function tests. Neurological function including hearing assessment should also be monitored.
|
||||||
|
Tương tác
Additive myelosuppressive effects w/ other myelosuppressive agents. Increased risk of nephrotoxicity and/or ototoxicity w/ aminoglycosides or diuretics. Excessive immunosuppression w/ risk of lymphoproliferation w/ ciclosporin. Increased risk of exacerbation of convulsions w/ phenytoin, fosphenytoin. Enhanced adverse/toxic effects of live attenuated vaccines.
Potentially Fatal: Risk of generalised disease mortal w/ yellow fever vaccine. |
||||||
|
Tác dụng
Description:
Mechanism of Action: Carboplatin is an alkylating agent which binds covalently to DNA. It modifies the cell cycle by interfering w/ DNA structure and function. Pharmacokinetics: Distribution: Widely distributed into body tissues and fluids, w/ highest concentrations in the kidney, liver, skin, and tumour tissue (as platinum). Volume of distribution: 16 L. Plasma protein binding: Irreversible (platinum). Metabolism: Undergoes minimal hepatic metabolism to aquated and hydroxylated compd. Excretion: Mainly via urine, approx a third of a dose is excreted unchanged. Terminal half-life: Approx 6 hr (as free platinum). |
||||||
|
Đặc tính
 Source: National Center for Biotechnology Information. PubChem Database. Carboplatin, CID=426756, https://pubchem.ncbi.nlm.nih.gov/compound/Carboplatin (accessed on Jan. 21, 2020) |
||||||
|
Bảo quản
Store at 25°C. Protect from light.
|
||||||
|
Phân loại MIMS
|
||||||
|
Phân loại ATC
L01XA02 - carboplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.
|
||||||
|
Tài liệu tham khảo
Anon. Carboplatin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 19/01/2016. Buckingham R (ed). Carboplatin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 19/01/2016. Carboplatin Injection Solution (Teva Parenteral Medicines, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 19/01/2016. McEvoy GK, Snow EK, Miller J et al (eds). Carboplatin. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 19/01/2016.
|
Đăng xuất
